Published in N Engl J Med on July 30, 1998
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother (2000) 8.54
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
Are we headed for a resurgence of the HIV epidemic among men who have sex with men? Am J Public Health (2001) 3.27
Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol (2003) 2.32
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc Natl Acad Sci U S A (2001) 2.02
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol (2002) 1.84
Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. J Virol (2005) 1.77
Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother (1999) 1.68
Barriers to HIV/AIDS treatment and treatment adherence among African-American adults with disadvantaged education. J Natl Med Assoc (1999) 1.51
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol (2000) 1.48
Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples. J Clin Microbiol (2001) 1.47
Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health (2000) 1.45
Patient-related factors predicting HIV medication adherence among men and women with alcohol problems. J Health Psychol (2007) 1.38
Comparative evaluation of three human immunodeficiency virus genotyping systems: the HIV-GenotypR method, the HIV PRT GeneChip assay, and the HIV-1 RT line probe assay. J Clin Microbiol (2000) 1.38
Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest ethiopia. AIDS Res Ther (2010) 1.35
The impact of alcohol use on the sexual scripts of HIV-positive men who have sex with men. J Sex Res (2004) 1.34
Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy. J Gen Intern Med (2003) 1.30
Taking antiretroviral therapy for HIV infection: learning from patients' stories. J Gen Intern Med (2000) 1.29
Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing. J Clin Microbiol (1999) 1.28
Discrimination against HIV-infected people and the spread of HIV: some evidence from France. PLoS One (2007) 1.27
Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect (2001) 1.27
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
Accelerated publication versus usual publication in 2 leading medical journals. CMAJ (2002) 1.20
Initiation and continuation of newer antiretroviral treatments among medicaid recipients with AIDS. J Gen Intern Med (2001) 1.19
Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease. J Virol (2002) 1.17
Sexually transmitted infections among HIV seropositive men and women. Sex Transm Infect (2000) 1.17
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Rev (2000) 1.15
Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS One (2011) 1.09
Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B. J Clin Microbiol (2003) 1.08
Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users. J Epidemiol Community Health (2002) 1.07
Infection of semen-producing organs by SIV during the acute and chronic stages of the disease. PLoS One (2008) 1.07
British HIV Association guidelines for prescribing antiretroviral therapy in pregnancy (1998). Sex Transm Infect (1999) 1.05
Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr (2008) 1.02
HIV infection of the male genital tract--consequences for sexual transmission and reproduction. Int J Androl (2009) 1.01
Molecular evidence of male-to-female sexual transmission of hepatitis C virus after vaginal and anal intercourse. J Clin Microbiol (2001) 1.01
When does overuse of antibiotics become a tragedy of the commons? PLoS One (2012) 0.99
Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA. J Acquir Immune Defic Syndr (2012) 0.97
A novel role for APOBEC3: susceptibility to sexual transmission of murine acquired immunodeficiency virus (mAIDS) is aggravated in APOBEC3 deficient mice. Retrovirology (2012) 0.96
Molecular approaches to diagnosing and managing infectious diseases: practicality and costs. Emerg Infect Dis (2001) 0.95
Enhancing HIV/AIDS and STD prevention through program integration. Public Health Rep (2004) 0.95
A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (2000) 0.95
Social factors affecting ART adherence in rural settings in Zambia. AIDS Care (2011) 0.94
Interventions for Enhancing Adherence to Antiretroviral Therapy (ART): A Systematic Review of High Quality Studies. AIDS Patient Care STDS (2015) 0.94
Mutagenically separated PCR assay for rapid detection of M41L and K70R zidovudine resistance mutations in CRF01_AE (subtype E) human immunodeficiency virus type 1. Antimicrob Agents Chemother (2002) 0.94
The repertoire of human efforts to avoid sexually transmissible diseases: past and present. Part 2: Strategies used during or after sex. Sex Transm Infect (2000) 0.94
Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS One (2011) 0.93
Trends and determining factors associated with adherence to antiretroviral therapy (ART) in Cameroon: a systematic review and analysis of the CAMPS trial. AIDS Res Ther (2012) 0.92
The repertoire of human efforts to avoid sexually transmissible diseases: past and present. Part 1: Strategies used before or instead of sex. Sex Transm Infect (2000) 0.92
A population-based and longitudinal study of sexual behavior and multidrug-resistant HIV among patients in clinical care. MedGenMed (2006) 0.91
Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor. Antimicrob Agents Chemother (2001) 0.90
In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression. J Acquir Immune Defic Syndr (2008) 0.90
Gender Power Inequality and Continued Sexual Risk Behavior among Racial/Ethnic Minority Adolescent and Young Adult Women Living with HIV. J AIDS Clin Res (2011) 0.90
When should we delay highly active antiretroviral therapy? J Gen Intern Med (1999) 0.89
Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther (2011) 0.89
Biomedical consequences of alcohol use disorders in the HIV-infected host. Curr HIV Res (2014) 0.88
Antiretroviral Drug Resistance in HIV-1. Curr Infect Dis Rep (1999) 0.87
Transmission of multidrug-resistant human immunodeficiency virus--the wake-up call. N Engl J Med (1998) 0.86
Exosomes in human semen restrict HIV-1 transmission by vaginal cells and block intravaginal replication of LP-BM5 murine AIDS virus complex. Virology (2015) 0.85
Antiviral drug resistance. BMJ (1998) 0.81
Optimal timing and duration of induction therapy for HIV-1 infection. PLoS Comput Biol (2007) 0.79
Brief screening for alcohol use disorders in HIV primary care. HIV Clin (2011) 0.79
Opportunities for sexual transmission of antiretroviral drug resistance among HIV-infected patients in care. AIDS (2013) 0.78
Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients. BMC Microbiol (2001) 0.77
Work-related barriers and facilitators to antiretroviral therapy adherence in persons living with HIV infection. AIDS Behav (2011) 0.77
Infection with HIV-1. BMJ (1998) 0.76
Computational Methods Applied to Rational Drug Design. Open Med Chem J (2016) 0.75
Update in internal medicine. Arch Med Res (2000) 0.75
Socioeconomic status and health. The challenge of the gradient. Am Psychol (1994) 13.59
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA (1998) 9.32
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 8.86
A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother (2000) 8.54
Socioeconomic inequalities in health. No easy solution. JAMA (1993) 7.11
Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors. J Virol (1987) 6.88
Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science (2000) 6.73
A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science (2000) 5.52
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med (2001) 5.33
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
HIV-1 protease inhibitors. A review for clinicians. JAMA (1997) 4.34
Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc Natl Acad Sci U S A (1993) 4.11
Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines. Science (1996) 3.84
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med (2001) 3.74
Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med (2001) 3.69
Gene expression profiling of cells, tissues, and developmental stages of the nematode C. elegans. Cold Spring Harb Symp Quant Biol (2003) 3.22
Depressive symptoms and CD4 lymphocyte decline among HIV-infected men. JAMA (1993) 2.93
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 2.91
A transmembrane guanylyl cyclase (DAF-11) and Hsp90 (DAF-21) regulate a common set of chemosensory behaviors in caenorhabditis elegans. Genetics (2000) 2.90
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2001) 2.84
Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA (1999) 2.82
Rapid HIV testing with same-day results: a field trial in Uganda. Int J STD AIDS (1998) 2.63
Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med (1989) 2.56
Contribution of increasing CO2 and climate to carbon storage by ecosystems in the United States. Science (2000) 2.51
High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest (1998) 2.47
Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting? Sex Transm Infect (2006) 2.45
Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother (2004) 2.44
Hematological reference ranges among healthy Ugandans. Clin Diagn Lab Immunol (1995) 2.44
Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome. The San Francisco Men's Health Study. JAMA (1987) 2.43
BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene (1998) 2.39
Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med (2001) 2.39
Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis (2000) 2.36
Living with discordance: knowledge, challenges, and prevention strategies of HIV-discordant couples in Uganda. AIDS Care (2005) 2.35
Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol (1999) 2.29
Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med (1995) 2.26
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med (1995) 2.26
How do medical residents discuss resuscitation with patients? J Gen Intern Med (1995) 2.20
Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA (2000) 2.20
Molecular characterization of two mammalian bHLH-PAS domain proteins selectively expressed in the central nervous system. Proc Natl Acad Sci U S A (1997) 2.15
Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med (2001) 2.13
Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci U S A (2000) 2.13
Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis (2000) 2.10
GIS-based measures of environmental equity: exploring their sensitivity and significance. J Expo Anal Environ Epidemiol (1999) 2.07
Immune dysregulation in TGF-beta 1-deficient mice. J Immunol (1994) 2.00
Regulated transcription of c-Ki-ras and c-myc during compensatory growth of rat liver. Mol Cell Biol (1984) 1.98
Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother (1998) 1.94
Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques. J Virol (1998) 1.94
Advances in quantitative PCR technology: 5' nuclease assays. Curr Opin Biotechnol (1998) 1.93
Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.88
Expression of a cellular oncogene during liver regeneration. Science (1983) 1.88
HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS (1999) 1.86
Comparison of blood pressure measured at the arm, ankle and calf. Anaesthesia (2008) 1.86
Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect (2001) 1.85
Requirement for transforming growth factor beta1 in controlling T cell apoptosis. J Exp Med (2001) 1.82
Production and application of electron vortex beams. Nature (2010) 1.76
The consequences of a positive prenatal HIV antibody test for women. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.74
Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. J Infect Dis (1999) 1.70
Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol (1995) 1.67
The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes (Lond) (2010) 1.61
Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. Proc Natl Acad Sci U S A (1997) 1.61
Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol (2009) 1.57
Depressive affect and survival among gay and bisexual men infected with HIV. Arch Intern Med (1996) 1.55
Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis (2000) 1.54
Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma. J Infect Dis (1996) 1.53
Impact of the ovulatory cycle on virologic and immunologic markers in HIV-infected women. J Infect Dis (2000) 1.51
See one, do one, teach one? House staff experience discussing do-not-resuscitate orders. Arch Intern Med (1996) 1.50
Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS (1999) 1.50
Diverse behavioural defects caused by mutations in Caenorhabditis elegans unc-43 CaM kinase II. Nature (1999) 1.50
A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J Virol (2000) 1.48
In vivo restoration of laminin 5 beta 3 expression and function in junctional epidermolysis bullosa. Proc Natl Acad Sci U S A (2001) 1.48
Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C. Diabetes Technol Ther (2003) 1.46
Primary HIV infection--a public health opportunity. Am J Public Health (1997) 1.44
Increasing prevalence of gestational diabetes mellitus in Chinese women from 1999 to 2008. Diabet Med (2011) 1.43
Does HIV reporting by name deter testing? MESH Study Group. AIDS (2000) 1.43
Feeding-based RNA interference of a trehalose phosphate synthase gene in the brown planthopper, Nilaparvata lugens. Insect Mol Biol (2010) 1.40
Arteriovenous fistula: a complication following renal biopsy of suspected bilateral Wilms' tumor. Med Pediatr Oncol (1997) 1.38
Infectivity of the human immunodeficiency virus: estimates from a prospective study of homosexual men. J Infect Dis (1987) 1.31
Can the poor adhere? Incentives for adherence to TB prevention in homeless adults. Int J Tuberc Lung Dis (2004) 1.31
Helper-independent retrovirus vectors with Rous-associated virus type O long terminal repeats. J Virol (1988) 1.29
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.28
Caregiver burden in HIV-positive and HIV-negative partners of men with AIDS. J Consult Clin Psychol (1994) 1.27
Interaction of workplace demands and cardiovascular reactivity in progression of carotid atherosclerosis: population based study. BMJ (1997) 1.26
Cell lineages in liver carcinogenesis: possible clues from studies of the distribution of alpha-fetoprotein RNA sequences in cell populations isolated from normal, regenerating, and preneoplastic rat livers. Cancer Res (1985) 1.25
Roles of a conserved arginine residue of DsbB in linking protein disulfide-bond-formation pathway to the respiratory chain of Escherichia coli. Proc Natl Acad Sci U S A (2000) 1.25
Associations between socioeconomic status and cardiovascular risk factors in an urban population in China. Bull World Health Organ (2000) 1.24
Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. Int J Behav Med (2003) 1.24
Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor beta 1 knockout mice. Proc Natl Acad Sci U S A (1994) 1.23